Metformin for Atrial Fibrillation — AHA 2025 (META-AF Trial)
Metformin for Atrial Fibrillation — AHA 2025 (META-AF Trial)
Source: AHA Medical News, AHA Scientific Sessions 2025 ( Nov 11, 2025)
Key Points
1. Background:
• Metformin, a long-used antidiabetic drug, may help reduce recurrent atrial arrhythmias after catheter ablation in overweight or obese patients without diabetes.
2. Study Design:
• META-AF was a randomized, open-label trial including 99 patients (49 metformin, 50 control).
• Participants were overweight/obese, non-diabetic, and followed for 1 year after AF ablation.
• Metformin started up to 6 weeks pre-ablation, titrated to max tolerated dose, continued for 12 months.
3. Main Findings:
• Freedom from recurrent AF/atrial arrhythmia:
• Metformin group: 78%
• Control group: 58%
• AF burden (days with AF): 8% (metformin) vs 16% (control), P = 0.02.
• Weight and HbA1c changes were modest (−6 kg vs −2 kg; NS).
4. Safety and Tolerability:
• Metformin was generally well-tolerated.
• 12 patients (≈25%) discontinued the drug, often because they felt asymptomatic.
5. Interpretation:
• Benefit appears independent of weight or glycemic effects.
6. Mechanistic Insight:
• Effect likely through AMP-activated protein kinase (AMPK) activation, a key cellular “self-protection” pathway.
• Metformin may have anti-arrhythmic properties beyond glucose lowering.
7. Context and Outlook:
• Despite newer agents (GLP-1 agonists, SGLT2 inhibitors), metformin remains cheap, safe, and mechanistically plausible for repurposing.
8. Caveats:
• Small sample size, open-label design, high dropout rate → exploratory, not definitive.
Quote:
“Even with the caveats, it’s worth seeing if the old dog can learn new tricks.” — George Schwartz, MD, PhD
